Denali Therapeutics Inc.

This early-stage study is testing an investigational drug called DNL593 to see if it is safe and how it behaves in the body. It involves healthy volunteers and people diagnosed with frontotemporal dementia (FTD) who have a specific genetic mutation. The main goal is to check for …

This early-stage study is testing an experimental drug called DNL126 in children with Sanfilippo syndrome type A, a rare and devastating genetic disorder that causes progressive brain damage. Researchers will assess the drug's safety, how it moves through the body, and look for e…

This study continues testing an experimental enzyme replacement therapy called DNL310 in people with Hunter syndrome (MPS II) who completed previous trials. It aims to understand the long-term safety and effectiveness of this treatment when given for up to five years. The therapy…